After Buying Galenea s RNAi IP, Nastech Expects To File IND for Flu Drug Around the End of 2006 | GenomeWeb

When Nastech Pharmaceutical last week unveiled its RNAi-based influenza drug development program and said it had acquired RNAi-related intellectual property and technology from Galenea (see RNAi News, 2/23/2006), it was expected that the bigger firm would be able to significantly accelerate the development of a key drug candidate covered under the deal.

What may not have been expected, however, is the degree to which Nastech plans to speed up the drug's R&D journey.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.